20 articles
TONTT2 tests whether erythropoietin dose and timing can be optimized to best preserve vision after traumatic optic neuropathy.
Italian researchers developed a biosensor to track extracellular vesicles in blood, potentially personalizing stroke rehabilitation.
Individualized brain training targets specific cognitive weaknesses in adults over 50 with HIV-associated thinking problems.
Researchers at Duke University tested a blood-based biomarker to stratify Alzheimer's patients from healthy adults, aiming to enable earlier detection.
A first-in-human multiple-ascending-dose trial tests Contraloid, an oral peptide designed to disassemble toxic amyloid-beta oligomers linked to Alzheimer's disease.
A Columbia University trial tests whether a hip hop-based dementia education program builds lasting literacy and reduces stigma in children and families.
A pilot RCT tested whether a smartphone app could improve quality of life and treatment adherence in HIV-positive patients aged 60+.
Small study reveals BDNF genetic variant could influence exercise's cognitive and cardiovascular benefits in healthy men.
A Phase 2 open-label trial explores whether an approved immune drug can raise frataxin protein levels and slow neurological decline in Friedreich Ataxia.
NGP 555 targets toxic brain protein production in healthy volunteers, offering potential early intervention for Alzheimer's prevention.
Small pilot study examined psilocybin's effects on brain circuits and emotion processing in healthy adults to understand abuse potential.
Mayo Clinic study reveals how early estrogen treatment affects brain blood flow and cognitive aging in postmenopausal women.
Nine-year study investigated whether solanezumab could slow memory decline in older adults with brain amyloid plaques.
Contraloid acetate, an oral all-D-peptide designed to disassemble toxic amyloid-beta oligomers, completed its first-in-human safety trial in 40 healthy volunteers.
Brain scans reveal how testosterone suppression in prostate cancer treatment could lead to cognitive decline in aging men.
A completed University of Kansas trial investigates whether creatine monohydrate can support brain energy metabolism in Alzheimer's patients.
A Phase 4 RCT tests whether one bevacizumab injection matches two combined doses for neovascular AMD outcomes over 12 months.
A Phase 1 trial of AV-1959R, an Aฮฒ-targeting vaccine, tests safety and antibody generation in healthy adults aged 40โ60.
French researchers followed 1,028 people with mild cognitive complaints to understand how dementia develops over time.
Clinical trial explores whether resetting gut microbiome through fecal transplants can slow Parkinson's progression and reduce symptoms.
